Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

Lectin-like domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharide-induced inflammatory response

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Shi, C. S.
  • Shi, G. Y.
  • Hsiao, S. M.
  • Kao, Y. C.
  • Kuo, K. L.
  • Ma, C. Y.
  • Kuo, C. H.
  • Chang, B. I.
  • Chang, C. F.
  • Wong, Chi-Huey
  • Wu, H. L.
  • Lin, Chun-Hung

publication date

  • November 2008

journal

  • Blood  Journal

abstract

  • Thrombomodulin (TM), a widely expressing glycoprotein originally identified in vascular endothelium, is an important cofactor in the protein C anticoagulant system. TM appears to exhibit anti-inflammatory ability through both protein C-dependent and -independent pathways. We presently have demonstrated that recombinant N-terminal lectinlike domain of TM (rTMD1) functions as a protective agent against sepsis caused by Gram-negative bacterial infections. rTMD1 caused agglutination of Escherichia coli and Klebsiella pneumoniae and enhanced the macrophage phagocytosis of these Gram-negative bacteria. Moreover, rTMD1 bound to the Klebsiella pneumoniae and lipopolysaccharide (LPS) by specifically interacting with Lewis Y antigen. rTMD1 inhibited LPS-induced inflammatory mediator production via interference with CD14 and LPS binding. Furthermore, rTMD1 modulated LPS-induced mitogen-activated protein kinase and nuclear factor-kappaB signaling pathway activations and inducible nitric oxide synthase expression in macrophages. Administration of rTMD1 protected the host by suppressing inflammatory responses induced by LPS and Gram-negative bacteria, and enhanced LPS and bacterial clearance in sepsis. Thus, rTMD1 can be used to defend against bacterial infection and inhibit LPS-induced inflammatory responses, suggesting that rTMD1 may be valuable in the treatment of severe inflammation in sepsis, especially in Gram-negative bacterial infections.

subject areas

  • Animals
  • Binding Sites
  • Cell Line
  • Gram-Negative Bacterial Infections
  • Humans
  • Inflammation
  • Klebsiella pneumoniae
  • Lewis Blood-Group System
  • Ligands
  • Lipopolysaccharides
  • MAP Kinase Signaling System
  • Macrophages
  • Male
  • Mice
  • NF-kappa B
  • Protein Structure, Tertiary
  • Recombinant Proteins
  • Sepsis
  • Signal Transduction
  • Thrombomodulin
scroll to property group menus

Identity

PubMed Central ID

  • PMC2572793

International Standard Serial Number (ISSN)

  • 0006-4971

Digital Object Identifier (DOI)

  • 10.1182/blood-2008-03-142760

PubMed ID

  • 18711002
scroll to property group menus

Additional Document Info

start page

  • 3661

end page

  • 3670

volume

  • 112

issue

  • 9

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support